<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119301</url>
  </required_header>
  <id_info>
    <org_study_id>05-028</org_study_id>
    <secondary_id>MSKCC-IRB-05028</secondary_id>
    <nct_id>NCT00119301</nct_id>
  </id_info>
  <brief_title>Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma</brief_title>
  <official_title>Phase I Study of High Dose Methotrexate With Simultaneous Trimetrexate and Leucovorin in Patients With Recurrent Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as methotrexate, trimetrexate glucuronate, and&#xD;
      leucovorin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of trimetrexate&#xD;
      glucuronate when given together with methotrexate and leucovorin in treating patients with&#xD;
      refractory or recurrent osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of trimetrexate glucuronate when administered with&#xD;
           high-dose methotrexate and leucovorin calcium in patients with refractory or recurrent&#xD;
           high-grade osteosarcoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the dose-limiting toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of trimetrexate glucuronate.&#xD;
&#xD;
      Patients receive high-dose methotrexate IV over 4 hours on days 1 and 8 and oral trimetrexate&#xD;
      glucuronate twice daily on days 2-6 and 9-13. Patients also receive leucovorin calcium IV&#xD;
      continuously over 24 hours or orally 2 or 4 times daily on days 9-14. Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of trimetrexate glucuronate until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 18 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) after 1 course of treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities as assessed by hematology and biochemistry testing on days 1, 8, and 28 of each course</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by radiographic response using RECIST criteria after every 2 courses of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by pathologic response using the Huvos grading system to evaluate post-treatment tumor necrosis at time of tumor resection after completion of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimetrexate glucuronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant osteosarcoma&#xD;
&#xD;
               -  High-grade disease&#xD;
&#xD;
          -  Recurrent or refractory disease after prior standard chemotherapy comprising&#xD;
             methotrexate, doxorubicin, cisplatin, and ifosfamide&#xD;
&#xD;
          -  No low-grade osteosarcoma&#xD;
&#xD;
          -  No parosteal or periosteal sarcoma&#xD;
&#xD;
          -  No osteosarcoma arising in premalignant bony lesions (e.g., Paget's disease) OR in a&#xD;
             prior radiotherapy field&#xD;
&#xD;
          -  No symptomatic or known brain or leptomeningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  1 to 35&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100% (for patients &gt; 16 years of age)&#xD;
&#xD;
          -  Lansky 70-100% (for patients ≤ 16 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times normal&#xD;
&#xD;
          -  AST and ALT ≤ 5 times normal&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  No clinically significant liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times normal OR&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ lower limit of&#xD;
             normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Shortening fraction ≥ 27% by echocardiogram OR&#xD;
&#xD;
          -  Ejection fraction ≥ 50% by gated radionuclide study&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled arterial hypertension&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of significant neurological or psychiatric disorder&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 7 days since prior biologic therapy&#xD;
&#xD;
          -  At least 6 months since prior allogeneic stem cell transplantation AND no evidence of&#xD;
             active graft-versus-host disease&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since prior substantial radiotherapy to the bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 30 days since prior and no other concurrent investigational drugs&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent participation in another clinical&#xD;
             trial&#xD;
&#xD;
          -  No concurrent medications that may interact with study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A. Meyers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <keyword>recurrent osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Trimetrexate</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

